Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Washington University School of Medicine
With
Novartis
National Institutes of Health (NIH)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
University of Pittsburgh
The primary objective is to determine if Carbamazepine therapy in patients with severe liver disease due to Alpha-1-Antitrypsin Deficiency leads to a significant reduction in the hepatic accumulation of ATZ.
The other objectives are:
To determine whether Carbamazepine treatment reduces hepatic fibrosis in alpha-1-antitrypsin deficient patients with severe liver disease. To determine whether Carbamazepine treatment reduces portal pressure in alpha-1-antitrypsin deficient patients with severe liver disease. To determine whether Carbamazepine treatment is safe and tolerated by patients with severe liver disease caused by alpha-1-deficiency. To determine whether Carbamazepine treatment leads to stabilization in disease severity as measured by the MELD scores.
Age
14–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age greater than or equal to 14 years to less than or equal to 80 years of age.
Alpha-1-Antitrypsin deficiency confirmed by ZZ or SZ phenotype \& serum level
\< 83mg/dl.
HVPG greater than or equal to 10 mmHg unless collateral vessels are visualized via transvenous biopsy.
You may not be if
Child Pugh Score greater than or equal to 12. Serum total bilirubin \> 5 mg/dl. INR \> 2.2.
Clareo Health | Carbamazepine in Severe Liver Disease Due to Alpha-1 Antitrypsin Deficiency
